Abstract
Background/Aims: Combined pH-metry/multichannel intraluminal impedance (pH/MII) measurement enables to measure gastroesophageal reflux despite ongoing proton pump inhibitor therapy. The aim of our study was to evaluate the influence of an escalating medical anti-reflux therapy with 40 mg esomeprazole, 80 mg esomeprazole and 80 mg esomeprazole plus baclofen for the treatment of refractory pathological reflux as determined by pH/MII. Methods: Symptomatic patients under 40 mg esomeprazole were screened by pH/MII. Patients with normal values in pH/MII were excluded; all others received 2 × 40 mg esomeprazole for another 4 weeks. Thereafter, the treatment effect was controlled by pH/MII. In the case of persistent pathological reflux, therapy was further escalated by adding baclofen and controlled after 3 months by pH/MII. Results: 45/138 (32.6%) patients showed pathological pH/MII despite ongoing therapy with 40 mg esomeprazole. In these, a significant reduction in liquid/mixed reflux events was observed after administering 2 × 40 mg (mean: 118.3 vs. mean: 66.6; p < 0.001), and pH/MII turned to normal in 32/45 (71.1%). Baclofen was additionally administered to 7/13 patients, which did not lead to a remarkable reduction in reflux events. Conclusion: In patients with abnormal pH/MII and persistent symptoms under 40 mg esomeprazole, we observed a significant reduction in liquid/mixed reflux events after increasing proton pump inhibitor dose up to 80 mg esomeprazole. Further escalation of therapy with baclofen has shown inconclusive results.
Journal Section:
Original Paper
References
1.
Sandler RS, Everhart JE, Donowitz M, Adams E, Cronin K, Goodman C, Gemmen E, Shah S, Avdic A, Rubin R: The burden of selected digestive diseases in the United States. Gastroenterology 2002;122:1500–1511.
[PubMed]
2.
Locke GR, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ: Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997;112:1448– 1456.
[PubMed]
3.
Issing WJ, Karkos PD, Perreas K, Folwaczny C, Reichel O: Dual-probe 24-hour ambulatory pH monitoring for diagnosis of laryngopharyngeal reflux. J Laryngol Otol 2004;118:845–848.
[PubMed]
4.
Shim KN, Hong SJ, Sung JK, Park KS, Kim SE, Park HS, Kim YS, Lim SH, Kim CH, Park MJ, Yim JY, Cho KR, Kim D, Park SJ, Jee SR, Kim JI, Park JY, Song GA, Jung HY, Lee YC, Kim JG, Kim JJ, Kim N, Park SH, Jung HC, Chung IS; The H. pylori and GERD Study Group of Korean College of Helicobacter and Upper Gastrointestinal Research: Clinical spectrum of reflux esophagitis among 25,536 Koreans who underwent a health check-up: a nationwide multicenter prospective, endoscopy-based study. J Clin Gastroenterol 2009; Epub ahead of print.
5.
Chiba N, De Gara CJ, Wilkinson JM, Hunt RH: Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997;112:1798–1810.
[PubMed]
6.
Armstrong D, Veldhuyzen van Zanten SJ, Barkun AN, Chiba N, Thomson AB, Smyth S, Sinclair P, Chakraborty B, White RJ; The CADET-HR Study Group: Heartburn-dominant, uninvestigated dyspepsia: a comparison of ‘PPI-start’ and ‘H2-RA-start’ management strategies in primary care – the CADET-HR Study. Aliment Pharmacol Ther 2005;21:1189–1202.
[PubMed]
7.
Fass R, Shapiro M, Dekel R, Sewell J: Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease – where next? Aliment Pharmacol Ther 2005;22:79–94.
[PubMed]
8.
Tutuian R, Vela MF, Hill EG, Mainie I, Agrawal A, Castell DO: Characteristics of symptomatic reflux episodes on acid suppressive therapy. Am J Gastroenterol 2008;103:1090–1096.
[PubMed]
9.
Bajbouj M, Becker V, Neuber M, Schmid RM, Meining A: Combined pH-metry/impedance monitoring increases the diagnostic yield in patients with atypical gastroesophageal reflux symptoms. Digestion 2007;76:223–228.
[PubMed]
10.
Mainie I, Tutuian R, Shay S, Vela M, Zhang X, Sifrim D, Castell DO: Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring. Gut 2006;55:1398–1402.
[PubMed]
11.
Zerbib F, Roman S, Ropert A, des Varannes SB, Pouderoux P, Chaput U, Mion F, Vérin E, Galmiche JP, Sifrim D: Esophageal pH-impedance monitoring and symptoms analysis in GERD: a study in patients off and on therapy. Am J Gastroenterol 2006;101:1956–1963.
[PubMed]
12.
Sifrim D, Castell D, Dent J, Kahrilas PJ: Gastroesophageal reflux monitoring: review and consensus report on detection and definitions of acid, non-acid, and gas reflux. Gut 2004;53:1024–1031.
[PubMed]
13.
Becker V, Bajbouj M, Waller K, Schmid RM, Meining A: Clinical trial: persistent gastro-oesophageal reflux symptoms despite standard therapy with proton pump inhibitors – a follow-up study of intraluminal-impedance guided therapy. Aliment Pharmacol Ther 2007;26:1355–1360.
[PubMed]
14.
Hemmink GJ, Bredenoord AJ, Weusten BL, Monkelbaan JF, Timmer R, Smout AJ: Esophageal pH-impedance monitoring in patients with therapy-resistant reflux symptoms: ‘on’ or ‘off’ proton pump inhibitor? Am J Gastroenterol 2008;103:2446–2453.
[PubMed]
15.
Koek GH, Sifrim D, Lerut T, Janssens J, Tack J: Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors. Gut 2003;52:1397–1402.
[PubMed]
16.
Savarino E, Zentilin P, Tutuian R, Pohl D, Casa DD, Frazzoni M, Cestari R, Savarino V: The role of nonacid reflux in NERD: lessons learned from impedance-pH monitoring in 150 patients off therapy. Am J Gastroenterol 2008;103:2685–2693.
[PubMed]
17.
El-Serag HB, Graham DY, Satia JA, Rabeneck L: Obesity is an independent risk factor for GERD symptoms and erosive esophagitis. Am J Gastroenterol 2005;100:2600–2601.
18.
Sifrim D, Mittal R, Fass R, Smout A, Castell D, Tack J, Gregersen H: Review article: acidity and volume of the refluxate in the genesis of gastro-oesophageal reflux disease symptoms. Aliment Pharmacol Ther 2007;25:1003–1017.
[PubMed]
19.
Jeske HC, Borovicka J, von Goedecke A, Tiefenthaler W, Hohlrieder M, Heidegger T, Benzer A: Preoperative administration of esomeprazole has no influence on frequency of refluxes. J Clin Anesth 2008;20:191–195.
[PubMed]
20.
Babaei A, Bhargava V, Aalam S, Scadeng M, Mittal R: Effect of proton pump inhibition on the gastric volume: assessed by magnetic resonance imaging. Aliment Pharmacol Ther 2009;29:863–870.
[PubMed]
21.
Rabasseda X, Cole P: Esomeprazole: a significant advance beyond omeprazole in the treatment of acid-related disease. Drugs Today (Barc) 2001;37:767–781.
[PubMed]
22.
Fass R, Sontag SJ, Traxler B, Sostek M: Treatment of patients with persistent heartburn symptoms: a double-blind randomized trial. Clin Gastroenterol Hepatol 2006;4:50–56.
[PubMed]
23.
Kahrilas PJ: When proton pump inhibitors fail. Clin Gastroenterol Hepatol 2008;6:482–483.
[PubMed]
24.
Sharma N, Agrawal A, Freeman J, Vela MF, Castell D: An analysis of persistent symptoms in acid-suppressed patients undergoing impedance-pH monitoring. Clin Gastroenterol Hepatol 2008;6:521–524.
[PubMed]
25.
Kahrilas PJ, Shaheen NJ, Vaezi MF; American Gastroenterological Association Institute; Clinical Practice and Quality Management Committee: American Gastroen- terological Association Institute technical review on the management of gastroesophageal reflux disease. Gastroenterology 2008;135:1392–1413, 1413.e1–5.
[PubMed]
26.
Jaspersen D, Nocon M, Labenz J, Leodolter A, Richter K, Stolte M, Vieth M, Lind T, Willich SN, Malfertheiner P: Clinical course of laryngo-respiratory symptoms in gastrooesophageal reflux disease during routine care: a 5-year follow-up. Aliment Pharmacol Ther 2009; Epub ahead of print.
27.
Robertson CS, Evans DF, Ledingham SJ, Atkinson M: Cisapride in the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1993;7:181–190.
[PubMed]
28.
Achem SR, Robinson M: A prokinetic approach to treatment of gastroesophageal reflux disease. Dig Dis 1998;16:38–46.
[PubMed]
29.
Castell DO, Sigmund C Jr, Patterson D, Lambert R, Hasner D, Clyde C, Zeldis JB: Cisapride 20 mg b.i.d. provides symptomatic relief of heartburn and related symptoms of chronic mild to moderate gastroesophageal reflux disease. CIS-USA-52 Investigator Group. Am J Gastroenterol 1998;93:547–552.
[PubMed]
30.
Blackshaw LA, Staunton E, Lehmann A, Dent J: Inhibition of transient LES relaxations and reflux in ferrets by GABA receptor agonists. Am J Physiol 1999;277:G867–G874.
[PubMed]
31.
Lehmann A, Antonsson M, Bremner-Danielsen M, Flärdh M, Hansson-Brändén L, Kärrberg L: Activation of the GABA(B) receptor inhibits transient lower esophageal sphincter relaxations in dogs. Gastroenterology 1999;117:1147–1154.
[PubMed]
32.
Ciccaglione AF, Marzio L: Effect of acute and chronic administration of the GABA B agonist baclofen on 24 hour pH metry and symptoms in control subjects and in patients with gastro-oesophageal reflux disease. Gut 2003;52:464–470.
[PubMed]
33.
Vela MF, Tutuian R, Katz PO, Castell DO: Baclofen decreases acid and non-acid post-prandial gastro-oesophageal reflux measured by combined multichannel intraluminal impedance and pH. Aliment Pharmacol Ther 2003;17:243–251.
[PubMed]
34.
Mainie I, Tutuian R, Agrawal A, Adams D, Castell DO: Combined multichannel intraluminal impedance-pH monitoring to select patients with persistent gastro-oesophageal reflux for laparoscopic Nissen fundoplication. Br J Surg 2006;93:1483–1487.
[PubMed]
35.
del Genio G, Tolone S, del Genio F, Rossetti G, Brusciano L, Pizza F, Fei L, del Genio A: Total fundoplication controls acid and nonacid reflux: evaluation by pre- and postoperative 24-h pH-multichannel intraluminal impedance. Surg Endosc 2008;22:2518–2523.
[PubMed]
36.
Katz PO: Medical therapy for gastroesophageal reflux disease in 2007. Rev Gastroenterol Disord 2007;7:193–203.
[PubMed]
© 2009 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2009
You do not currently have access to this content.
